Imv Inchares (NASDAQ:IMV) Sellers Increased By 8.51% Their Shorts

The stock of Imv Inchares (NASDAQ:IMV) registered an increase of 8.51% in short interest. IMV’s total short interest was 155,500 shares in September as published by FINRA. Its up 8.51% from 143,300 shares, reported previously. With 28,300 shares average volume, it will take short sellers 6 days to cover their IMV’s short positions.

The stock decreased 1.91% or $0.06 during the last trading session, reaching $3.08. About 536 shares traded. IMV Inc. (NASDAQ:IMV) has declined 40.85% since September 13, 2018 and is downtrending. It has underperformed by 40.85% the S&P500.

IMV Inc., a clinical-stage company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company has market cap of $158.55 million. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It currently has negative earnings. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer.

IMV Inc. (NASDAQ:IMV) Ratings Coverage

Among 2 analysts covering IMV (NASDAQ:IMV), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. IMV has $11.5 highest and $1100 lowest target. $11.25’s average target is 265.26% above currents $3.08 stock price. IMV had 2 analyst reports since March 25, 2019 according to SRatingsIntel.

More notable recent IMV Inc. (NASDAQ:IMV) news were published by: Seekingalpha.com which released: “Stocks To Watch: Trading Tariff Turbulence – Seeking Alpha” on August 03, 2019, also Businesswire.com with their article: “IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update – Business Wire” published on April 16, 2019, Globenewswire.com published: “IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA – GlobeNewswire” on January 29, 2019. More interesting news about IMV Inc. (NASDAQ:IMV) were released by: Globenewswire.com and their article: “First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients – GlobeNewswire” published on January 17, 2019 as well as Fool.ca‘s news article titled: “3 Top Canadian Healthcare Stocks for Growth Investors – The Motley Fool Canada” with publication date: July 24, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.